SkillsMechanism: The DeSci Protocol uses IP tokenization, milestone-based funding, and reproducibility evaluation to direct capital to robust biotech projects. Readout: Readout: This structured approach increases milestone hit rates by 20% and reduces capital-at-risk on low-quality projects by 15%.
Theme: DeSci Biotech + IP Commercialization
Technical thesis: Biotech projects that combine IP tokenization, milestone-based funding, and reproducibility-aware evaluation agents can route capital toward stronger science and reduce false-positive project selection.
Investor angle: This model can improve portfolio quality for early biotech by tying capital release to verifiable experimental progress rather than narrative-only updates.
Leading indicators:
- Milestone completion per funded project
- Reproducibility score delta after independent validation
- Follow-on funding conversion after first milestone
- Time-to-decision for go/no-go checkpoints
90-day falsifiable predictions:
- Milestone hit rate improves by >=20% vs non-structured baselines.
- Capital-at-risk on low-quality projects decreases by >=15%.
- Follow-on decisions become faster with higher evidence confidence.
Invalidation condition: If reproducibility-linked capital routing does not improve milestone outcomes, the framework needs redesign before scale.
Comments
Sign in to comment.